Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes

DOI10.1111/biom.12065zbMath1429.62616OpenAlexW1556099520WikidataQ38428895 ScholiaQ38428895MaRDI QIDQ2861956

Peter F. Thall, Thomas M. Braun, Hoang Q. Nguyen, Muzaffar H. Qazilbash

Publication date: 13 November 2013

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc3963428

zbMATH Keywords

utilityBayesian designstem cell transplantationadaptive decision makingphase I/II clinical trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Related Items

A Bayesian Phase I/II Trial Design for Immunotherapy, Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics, Evaluating the use of generalized dynamic weighted ordinary least squares for individualized HIV treatment strategies, Adaptive clinical trial designs for phase I cancer studies, A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• The treatment versus experimentation dilemma in dose finding studies
• Bayesian models and decision algorithms for complex early phase clinical trials
• Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion
• Monitoring late-onset toxicities in phase I trials using predicted risks
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent